Articles

Rajat Bannerji, MD, PhD, discusses the clinical activity of the bispecific antibody REGN1979 in patients with non-Hodgkin lymphoma.

Bispecific Antibody Is Highly Active in Relapsed/Refractory Non-Hodgkin Lymphoma

Videos

Howard S. Hochster, MD, FACP, discusses important takeaways from the randomized, double-blind, phase III POLO trial in pancreatic cancer. 
 

Dr. Hochster on Take-Home Message of the POLO Trial in Pancreatic Cancer

Howard Hochster, MD, FACP, associate director for clinical research and director, Gastrointestinal Oncology, Rutgers Cancer Institute of New Jersey, director of oncology research, RWJBarnabas Health, discusses the safety analysis of TAS-102 in metastatic colorectal cancer and metastatic gastric/gastroesophageal junction cancer.

Dr. Hochster on the Safety Analysis of TAS-102 in CRC and Gastric/GEJ Cancer

Jyoti Malhotra, MD, MPH, discusses a phase I multicenter trial of PD-1 blockade with pembrolizumab with concurrent chemoradiation in patients with locally advanced, unresectable non–small cell lung cancer.

Dr. Malhotra on Pembrolizumab During Concurrent Chemoradiation in NSCLC

Rutgers Cancer Institute of New Jersey, the state’s only Comprehensive Cancer Center as recognized by the National Cancer Institute, has been awarded a $15.1 million grant as part of its successful 2019 redesignation. 

$15.1M Awarded to Rutgers Cancer Institute of New Jersey for Redesignation as the State's Only Comprehensive Cancer Center

Recently approved therapy is administered through program at New Jersey’s Only National Cancer Institute-designated Comprehensive Cancer Center.

Rutgers Cancer Institute of New Jersey

Latest from Rutgers Cancer Institute of New Jersey

New content coming soon, please check back later.